A Woburn biotechnology company laid off more than 200 Massachusetts employees last week, and state filings warn more cuts may be coming.
Replimune Group Inc. spokesperson Arleen Goldenberg confirmed to MassLive that 224 employees were laid off across two facilities, all resulting from the U.S. Food and Drug Administration’s April 10 decision to reject the company’s lead cancer drug.
The first wave, which began April 13, eliminated 63 positions from the company’s commercial organization at its Woburn headquarters…